This level of PRO assessment in an MBC registry study is unique to SystHERs and may provide valuable information regarding the experience of patients with HER2-positive breast cancer receiving treatment for metastatic disease and help patients and their clinicians make more informed treatment choices. This evidence concerns the gene ERBB2 and breast carcinoma.